[go: up one dir, main page]

MX2022012635A - Composiciones y métodos para distribución de barrera hematoencefálica. - Google Patents

Composiciones y métodos para distribución de barrera hematoencefálica.

Info

Publication number
MX2022012635A
MX2022012635A MX2022012635A MX2022012635A MX2022012635A MX 2022012635 A MX2022012635 A MX 2022012635A MX 2022012635 A MX2022012635 A MX 2022012635A MX 2022012635 A MX2022012635 A MX 2022012635A MX 2022012635 A MX2022012635 A MX 2022012635A
Authority
MX
Mexico
Prior art keywords
blood
antigen
brain barrier
compositions
distribution
Prior art date
Application number
MX2022012635A
Other languages
English (en)
Inventor
Sanjaya Singh
Suzanne Edavettal
Deepti Wilkinson
Brian Geist
Derrick Domingo
Pilar Cejudo-Martin
Pharavee Jaisprasart
Original Assignee
Aliada Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aliada Therapeutics Inc filed Critical Aliada Therapeutics Inc
Publication of MX2022012635A publication Critical patent/MX2022012635A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen anticuerpos anti-TfR monoclonales y fragmentos de unión al antígeno de los mismos para distribución de un agente hacia el cerebro de un sujeto en necesidad de los mismos; también se describen conjugados y constructos de fusión que contienen el anticuerpo anti-TfR o fragmento de unión al antígeno del mismo acoplado a un agente terapéutico o de diagnóstico, tal como un segundo anticuerpo y fragmento de unión al antígeno del mismo, para tratar o detectar un trastorno neurológico y/o distribuir un agente terapéutico o de diagnóstico a través de la barrera hematoencefálica; también se describen ácidos nucleicos que codifican los anticuerpos, conjugados y constructos de fusión y células huésped recombinantes relacionadas.
MX2022012635A 2020-04-08 2021-04-07 Composiciones y métodos para distribución de barrera hematoencefálica. MX2022012635A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063006998P 2020-04-08 2020-04-08
US202063036020P 2020-06-08 2020-06-08
PCT/IB2021/052889 WO2021205358A1 (en) 2020-04-08 2021-04-07 Compositions and methods for blood-brain barrier delivery

Publications (1)

Publication Number Publication Date
MX2022012635A true MX2022012635A (es) 2023-01-11

Family

ID=78022500

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012635A MX2022012635A (es) 2020-04-08 2021-04-07 Composiciones y métodos para distribución de barrera hematoencefálica.

Country Status (13)

Country Link
US (2) US20230174646A1 (es)
EP (1) EP4132589A4 (es)
JP (1) JP2023520821A (es)
KR (1) KR20220164773A (es)
CN (1) CN116096427B (es)
AR (2) AR127521A2 (es)
AU (1) AU2021253820A1 (es)
BR (1) BR112022020275A2 (es)
CA (1) CA3179911A1 (es)
IL (1) IL297148A (es)
MX (1) MX2022012635A (es)
TW (1) TW202204413A (es)
WO (1) WO2021205358A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220166308A (ko) * 2020-04-08 2022-12-16 얀센 바이오테크 인코포레이티드 항-phf-타우 항체 및 이의 용도
KR20240156640A (ko) 2022-03-11 2024-10-30 얀센 파마슈티카 엔브이 다중특이적 항체 및 이의 용도
CN119173530A (zh) 2022-03-11 2024-12-20 詹森药业有限公司 多特异性抗体及其用途
CA3254098A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv MULTISPECIFIC ANTIBODIES AND THEIR USES
CA3246997A1 (en) * 2022-03-31 2023-10-05 The Wistar Institute Of Anatomy And Biology ANTIBODIES AGAINST HUMAN SIGLEC-7 AND THEIR USE IN IMMUNOTHERAPY
EP4547716A2 (en) * 2022-07-01 2025-05-07 Denali Therapeutics Inc. Transferrin receptor binding molecule conjugates for delivery of oligonucleotides to cells
JP2025528752A (ja) * 2022-07-29 2025-09-02 アレクトル エルエルシー トランスフェリン受容体抗原結合ドメイン及びその使用法
EP4565330A1 (en) * 2022-08-05 2025-06-11 Janssen Biotech, Inc. Transferrin receptor binding proteins for treating brain tumors
WO2025024334A1 (en) 2023-07-21 2025-01-30 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025021790A2 (en) * 2023-07-24 2025-01-30 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2025172924A1 (en) 2024-02-15 2025-08-21 Janssen Biotech, Inc. Anti-transferrin receptor compositions and methods thereof
WO2025230358A1 (ko) * 2024-05-03 2025-11-06 한양대학교 산학협력단 엔도좀 탈출 효율이 향상된 항 인간 트랜스페린 수용체 항체, 및 이를 이용한 다중특이적 항체 및 약학 조성물
CN119192378B (zh) * 2024-10-16 2025-10-17 中国人民解放军军事科学院军事医学研究院 一种pH敏感型人源抗转铁蛋白受体1抗体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006060419A2 (en) * 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
EA034333B1 (ru) * 2010-11-30 2020-01-29 Дженентек, Инк. Варианты антитела для переноса соединения через гематоэнцефалический барьер
RU2013150331A (ru) * 2011-04-20 2015-05-27 Рош Гликарт Аг СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
EP3594239B1 (en) * 2012-05-21 2024-10-30 F. Hoffmann-La Roche AG Methods for improving safety of blood-brain barrier transport
JP2016501881A (ja) * 2012-12-04 2016-01-21 アッヴィ・インコーポレイテッド 血液脳関門（ｂｂｂ）を透過する二重特異性結合タンパク質
PL3594240T3 (pl) * 2013-05-20 2024-04-02 F. Hoffmann-La Roche Ag Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania
RU2694659C2 (ru) * 2014-01-06 2019-07-16 Ф. Хоффманн-Ля Рош Аг Одновалентные модули-переносчики через гематоэнцефалический барьер
EP3221362B1 (en) * 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
US11008403B2 (en) * 2014-11-19 2021-05-18 Genentech, Inc. Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
US10179817B2 (en) * 2015-05-04 2019-01-15 Cytomx Therapeutics, Inc. Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
DK3313879T3 (da) * 2015-06-24 2022-03-14 Hoffmann La Roche Anti-transferrinreceptor-antistoffer med tilpasset affinitet
JP2019529345A (ja) * 2016-07-14 2019-10-17 バイオアークティック アクティエボラーグ 脳送達タンパク質
UY37931A (es) * 2017-10-14 2019-04-30 Abbvie Inc Conjugados de anticuerpo activable anti-cd71 y fármaco y sus métodos de uso
WO2019089395A1 (en) * 2017-11-02 2019-05-09 Ossianix, Inc. Improved tfr-selective binding peptides capable of crossing the blood brain barrier
EP3806962A1 (en) * 2018-06-13 2021-04-21 Novartis AG Bcma chimeric antigen receptors and uses thereof
WO2020061498A1 (en) * 2018-09-20 2020-03-26 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd123 immunotherapy

Also Published As

Publication number Publication date
US20230174646A1 (en) 2023-06-08
EP4132589A1 (en) 2023-02-15
TW202204413A (zh) 2022-02-01
AR127521A2 (es) 2024-01-31
EP4132589A4 (en) 2024-05-08
CA3179911A1 (en) 2021-10-14
CN116096427A (zh) 2023-05-09
US20260008846A1 (en) 2026-01-08
WO2021205358A1 (en) 2021-10-14
JP2023520821A (ja) 2023-05-19
CN116096427B (zh) 2025-11-28
AR127520A2 (es) 2024-01-31
IL297148A (en) 2022-12-01
KR20220164773A (ko) 2022-12-13
AU2021253820A1 (en) 2022-11-24
BR112022020275A2 (pt) 2022-12-27

Similar Documents

Publication Publication Date Title
MX2022012635A (es) Composiciones y métodos para distribución de barrera hematoencefálica.
AR127518A2 (es) Anticuerpos anti-cd98 y usos de estos
PE20211284A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
RU2018139811A (ru) Мультиспецифические антигенсвязывающие конструкции, нацеливающие иммунотерапевтические средства
MX2019015742A (es) Receptores de celulas t novedosos, e inmunoterapia usando los mismos.
BR112022009679A2 (pt) Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos
BR112015010046A2 (pt) Proteínas de ligação a antígeno ou um fragmento de ligação a antígeno da mesma e seu método de produção, vetor, célula hospedeira de microrganismo transgênico, imunoconjugado e seu uso, composição farmacêutica e hibridoma murino
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
CO6351751A2 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
FI3736291T3 (fi) Anti-fcrh5-vasta-aineita
PE20191786A1 (es) Anticuerpo monoclonal para pd-l1
BR112021017046A2 (pt) Receptores de antígeno quiméricos antirreceptores de folato 1 humanizados e seus usos
ES3036457T3 (en) A cd33-, cd16- and cd123-specific single chain triplebody
NZ750948A (en) Anti-gp73 antibodies and immunoconjugates
AR121803A1 (es) Composiciones y métodos para suministro a la barrera hematoencefálica
CO2025009946A2 (es) Proteínas de unión al antígeno anti-tnfr2 y sus usos
AR121802A1 (es) Anticuerpos anti-cd98 y usos de estos
MX2024011081A (es) Anticuerpos multiespecíficos y usos de estos.
MX2022004058A (es) Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.
US20210147545A1 (en) Immunotoxins for use in treating cancer
AR132867A1 (es) Anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente a axl, y uso del mismo
UY39687A (es) Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo
MX2025000487A (es) Anticuerpos anti-mesotelina
Schuurmans et al. In-vivo analysis determining neuroblastoma targeting potential of aGD2-SIRPα fusion antibodies for local CD47 blockade
AR129553A1 (es) Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente a bcma, y uso del mismo